# UCN2

## Overview
Urocortin 2 (UCN2) is a gene that encodes the peptide hormone urocortin 2, a member of the corticotropin-releasing factor (CRF) family. This peptide is primarily involved in cardiovascular and metabolic regulation, exerting its effects through interaction with the corticotropin-releasing hormone receptor type 2 (CRF-R2). Urocortin 2 is characterized by its ability to induce vasodilation and enhance cardiac function, as well as modulate glucose metabolism and insulin sensitivity. The peptide's activity is mediated by various intracellular signaling pathways, including those involving adenylyl cyclase, protein kinase A (PKA), and mitogen-activated protein kinases (MAPKs). Urocortin 2's role in cardioprotection and its potential implications in cancer and metabolic disorders underscore its clinical significance (Gao2014Urocortin2; Adão2015Urocortin; Flaherty2023Chronic).

## Structure
Urocortin 2 (UCN2) is a peptide belonging to the corticotropin-releasing factor (CRF) family, characterized by its specific amino acid sequence and structural features. The primary structure of UCN2 includes a sequence that is crucial for its interaction with type 2 CRF receptors (CRF-R2), while showing low affinity for type 1 CRF receptors (CRF-R1) (Reyes2001Urocortin; Vaughan2013Posttranslational). 

The secondary structure of UCN2 is likely to include alpha helices, which are common in peptides of this family, contributing to its stability and receptor binding capabilities (Isfort2006Modifications). The tertiary structure involves the three-dimensional folding necessary for its biological function, although specific details on this folding are not provided in the context.

Post-translational modifications play a significant role in the bioactivity of UCN2. Amidation at the C-terminus is crucial for receptor activation, with amidated peptides showing high potency in activating CRF-R2 (Vaughan2013Posttranslational). Glycosylation is another modification that affects the stability and bioavailability of UCN2, particularly in the human variant, which is heavily glycosylated (Vaughan2013Posttranslational). These modifications are essential for the peptide's interaction with its receptors and its overall pharmacological properties.

## Function
Urocortin 2 (UCN2) is a peptide hormone that plays a significant role in cardiovascular and metabolic functions in healthy human cells. It primarily interacts with the corticotropin-releasing hormone receptor type 2 (CRH-R2), activating several intracellular signaling pathways. One of the main pathways involves adenylyl cyclase and cyclic adenosine monophosphate (cAMP), leading to protein kinase A (PKA) activation, which influences gene transcription and post-translational modifications (Adão2015Urocortin).

UCN2 is involved in vasodilation, reducing arterial blood pressure through peripheral CRH-R2 receptors. This vasodilation is mediated by nitric oxide (NO) release, which stimulates Ca2+-activated K+ channels in vascular smooth muscle via cGMP-dependent pathways (Adão2015Urocortin). In cardiac myocytes, UCN2 enhances myocardial inotropy and lusitropy, improving intracellular calcium handling and cardiac performance (Adão2015Urocortin).

In skeletal muscle, UCN2 modulates glucose utilization and insulin sensitivity. It inhibits insulin signaling pathways, affecting insulin-induced phosphorylation of Akt and ERK1/2, which may play a role in glucose homeostasis during metabolic challenges (Chen2006Urocortin). UCN2's activity in these pathways suggests its involvement in maintaining energy balance and cardiovascular health.

## Clinical Significance
Alterations in the expression of the UCN2 gene have been implicated in various diseases and conditions. In colorectal cancer (CRC), diminished expression of the corticotropin-releasing hormone receptor 2 (CRHR2), which interacts with UCN2, is associated with tumor growth and epithelial-to-mesenchymal transition (EMT). This is linked to persistent interleukin-6 (IL-6)/Stat3 signaling, promoting inflammation and tumorigenesis. CRHR2/Ucn2 signaling acts as a negative regulator of tumor growth and EMT, suggesting that alterations in this pathway could contribute to CRC progression and metastasis (Rodriguez2015Diminished).

In laryngeal cancer, the formation of a chimeric transcript involving UCN2, known as COL7A1-UCN2, has been identified. This chimera is associated with down-regulation of UCN2 and is linked to increased tumor invasiveness and poor clinical prognosis. The disruption of UCN2 expression due to this chimera may lead to the loss of its tumor suppressor function, impacting tumor vascularization, proliferation, and invasion (Tao2018Identification).

In metabolic disorders, UCN2 has shown contradictory effects on insulin sensitivity. Acute UCN2 treatment induces insulin resistance, while chronic elevation improves glucose tolerance, suggesting that alterations in UCN2 levels can significantly impact glucose metabolism and insulin sensitivity (Flaherty2023Chronic).

## Interactions
Urocortin 2 (UCN2) interacts with several proteins and signaling pathways, primarily through its binding to the corticotropin-releasing factor receptor 2 (CRFR2). This interaction is crucial for its role in cardioprotection, particularly during ischemia/reperfusion injury. UCN2 activates AMP-activated protein kinase (AMPK) in cardiomyocytes, a process mediated by CRFR2 and involving protein kinase C epsilon (PKCε) (Li2013Urocortin). UCN2 also modulates the mitogen-activated protein kinase (MAPK) pathways by inhibiting p38-MAPK, which is associated with pro-apoptotic processes, and activating ERK1/2, linked to anti-apoptotic effects (Gao2014Urocortin2).

In addition to its effects on MAPK signaling, UCN2 influences the Bcl-2 family of proteins, increasing the expression of the anti-apoptotic protein Bcl-2 and reducing the activation of the pro-apoptotic protein Bax. This regulation is important for maintaining mitochondrial stability and cell survival during cardiac stress (Gao2014Urocortin2). UCN2's interactions with these proteins and pathways highlight its role in modulating cellular responses to stress and injury, particularly in the cardiovascular system.


## References


[1. (Gao2014Urocortin2) Xiu-Fang Gao, Yue Zhou, Da-Ying Wang, Kar-Sheng Lew, Arthur Mark Richards, and Peipei Wang. Urocortin-2 suppression of p38-mapk signaling as an additional mechanism for ischemic cardioprotection. Molecular and Cellular Biochemistry, 398(1–2):135–146, September 2014. URL: http://dx.doi.org/10.1007/s11010-014-2213-1, doi:10.1007/s11010-014-2213-1. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11010-014-2213-1)

[2. (Tao2018Identification) Ye Tao, Neil Gross, Xiaojiao Fan, Jianming Yang, Maikun Teng, Xu Li, Guojun Li, Yang Zhang, and Zhigang Huang. Identification of novel enriched recurrent chimeric col7a1-ucn2 in human laryngeal cancer samples using deep sequencing. BMC Cancer, March 2018. URL: http://dx.doi.org/10.1186/s12885-018-4161-8, doi:10.1186/s12885-018-4161-8. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-018-4161-8)

[3. (Reyes2001Urocortin) T. M. Reyes, K. Lewis, M. H. Perrin, K. S. Kunitake, J. Vaughan, C. A. Arias, J. B. Hogenesch, J. Gulyas, J. Rivier, W. W. Vale, and P. E. Sawchenko. Urocortin ii: a member of the corticotropin-releasing factor (crf) neuropeptide family that is selectively bound by type 2 crf receptors. Proceedings of the National Academy of Sciences, 98(5):2843–2848, February 2001. URL: http://dx.doi.org/10.1073/pnas.051626398, doi:10.1073/pnas.051626398. This article has 709 citations.](https://doi.org/10.1073/pnas.051626398)

[4. (Li2013Urocortin) Ji Li, Dake Qi, Haiying Cheng, Xiaoyue Hu, Edward J. Miller, Xiaohong Wu, Kerry S. Russell, Nicole Mikush, Jiasheng Zhang, Lei Xiao, Robert S. Sherwin, and Lawrence H. Young. Urocortin 2 autocrine/paracrine and pharmacologic effects to activate amp-activated protein kinase in the heart. Proceedings of the National Academy of Sciences, 110(40):16133–16138, September 2013. URL: http://dx.doi.org/10.1073/pnas.1312775110, doi:10.1073/pnas.1312775110. This article has 30 citations.](https://doi.org/10.1073/pnas.1312775110)

[5. (Vaughan2013Posttranslational) Joan M. Vaughan, Cynthia J. Donaldson, Wolfgang H. Fischer, Marilyn H. Perrin, Jean E. Rivier, Paul E. Sawchenko, and Wylie W. Vale. Posttranslational processing of human and mouse urocortin 2: characterization and bioactivity of gene products. Endocrinology, 154(4):1553–1564, April 2013. URL: http://dx.doi.org/10.1210/en.2012-2011, doi:10.1210/en.2012-2011. This article has 8 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1210/en.2012-2011)

[6. (Adão2015Urocortin) Rui Adão, Diana Santos-Ribeiro, Miriam T. Rademaker, Adelino F. Leite-Moreira, and Carmen Brás-Silva. Urocortin 2 in cardiovascular health and disease. Drug Discovery Today, 20(7):906–914, July 2015. URL: http://dx.doi.org/10.1016/j.drudis.2015.02.012, doi:10.1016/j.drudis.2015.02.012. This article has 22 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.drudis.2015.02.012)

[7. (Isfort2006Modifications) Robert J. Isfort, Feng Wang, Michelle Tscheiner, Elizabeth Dolan, Mary Beth Bauer, Frank Lefever, Deborah Reichart, Kenneth R. Wehmeyer, Raymond A. Reilman, Bradly D. Keck, Richard T. Hinkle, and Adam W. Mazur. Modifications of the human urocortin 2 peptide that improve pharmacological properties. Peptides, 27(7):1806–1813, July 2006. URL: http://dx.doi.org/10.1016/j.peptides.2006.01.003, doi:10.1016/j.peptides.2006.01.003. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.peptides.2006.01.003)

[8. (Chen2006Urocortin) Alon Chen, Bhawanjit Brar, Cheol Soo Choi, David Rousso, Joan Vaughan, Yael Kuperman, Shee Ne Kim, Cindy Donaldson, Sean M. Smith, Pauline Jamieson, Chien Li, Tim R. Nagy, Gerald I. Shulman, Kuo-Fen Lee, and Wylie Vale. Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proceedings of the National Academy of Sciences, 103(44):16580–16585, October 2006. URL: http://dx.doi.org/10.1073/pnas.0607337103, doi:10.1073/pnas.0607337103. This article has 60 citations.](https://doi.org/10.1073/pnas.0607337103)

[9. (Flaherty2023Chronic) Stephen E. Flaherty, Olivier Bezy, Wei Zheng, Dong Yan, Xiangping Li, Srinath Jagarlapudi, Bina Albuquerque, Ryan M. Esquejo, Matthew Peloquin, Meriem Semache, Arturo Mancini, Liya Kang, Doreen Drujan, Susanne B. Breitkopf, John D. Griffin, Pierre M. Jean Beltran, Liang Xue, John Stansfield, Evanthia Pashos, Quazi Shakey, Christian Pehmøller, Mara Monetti, Morris J. Birnbaum, Jean-Philippe Fortin, and Zhidan Wu. Chronic ucn2 treatment desensitizes crhr2 and improves insulin sensitivity. Nature Communications, July 2023. URL: http://dx.doi.org/10.1038/s41467-023-39597-w, doi:10.1038/s41467-023-39597-w. This article has 3 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-39597-w)

[10. (Rodriguez2015Diminished) Jorge A. Rodriguez, Sara Huerta-Yepez, Ivy Ka Man Law, Guillermina J. Baay-Guzman, Belen Tirado-Rodriguez, Jill M. Hoffman, Dimitrios Iliopoulos, Daniel W. Hommes, Hein W. Verspaget, Lin Chang, Charalabos Pothoulakis, and Stavroula Baritaki. Diminished expression of corticotropin-releasing hormone receptor 2 in human colon cancer promotes tumor growth and epithelial-to-mesenchymal transition via persistent interleukin-6/stat3 signaling. Cellular and Molecular Gastroenterology and Hepatology, 1(6):610–630, November 2015. URL: http://dx.doi.org/10.1016/j.jcmgh.2015.08.001, doi:10.1016/j.jcmgh.2015.08.001. This article has 33 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jcmgh.2015.08.001)